WILGO RESEARCH INDEX
Selank
Selank is a synthetic heptapeptide derived from the tuftsin family. Published research includes Russian human comparative studies in anxiety disorders as well as animal and molecular work on stress-related behavior, enkephalin metabolism, and gene-expression pathways.
HeptapeptideTuftsin analogAnxiety researchHuman comparative studiesNeurobiology
EVIDENCE MAP
What kind of evidence exists?
Selank has human publications, but the evidence base is geographically concentrated and much smaller than that of established anxiolytic therapies.
A PubMed record is not the same thing as broad clinical validation.
Selank has published human work, but the research base is relatively small and concentrated. WILGO therefore presents it as investigational evidence, not an established standard of care.
PUBLISHED LITERATURE
Selected studies.
Selected sources are grouped by study type so model limitations remain visible.
HUMAN · COMPARATIVE
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Sixty-two patients with generalized anxiety disorder or neurasthenia were studied, with Selank compared against medazepam. The publication reported similar anxiolytic effects and measured serum enkephalin-related activity.
HUMAN · COMPARATIVE
A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders
This comparative human publication reported anxiolytic effects and tolerability outcomes, including persistence of effect after treatment. Independent replication remains limited.
PRECLINICAL · STRESS
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Rat experiments examined Selank alone and with diazepam under chronic mild stress, reporting behavioral changes in elevated-plus-maze testing.
PRECLINICAL · LEARNING
The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats
Repeated Selank administration was associated with improved learning performance in rats with initially poor learning ability.
MECHANISTIC · ENKEPHALINS
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity
This work investigated whether effects on enkephalin-degrading enzymes could contribute to Selank’s proposed anxiolytic mechanism.
REVIEW · MOLECULAR
The Molecular Aspects of Heptapeptide Selank Biological Activity
A review of molecular pathways and gene-expression findings associated with the heptapeptide Selank.
REFERENCES
Primary sources.
Direct PubMed links are used wherever possible.
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurastheniaPMID 18454096 · PubMed →
A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disordersPMID 25176261 · PubMed →
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats2017 · PMID 28280289 · DOI 10.1155/2017/5091027 · PubMed →
The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in ratsPMID 14552529 · DOI 10.1023/A:1024444321191 · PubMed →
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activityPMID 11550013 · PubMed →
The Molecular Aspects of Heptapeptide Selank Biological ActivityPMID 30255741 · PubMed →
Research-use notice: This resource summarizes published scientific literature for informational and research-reference purposes. It does not provide medical advice, dosing, reconstitution, injection, therapeutic, diagnostic, or other human-use instructions. WILGO products are intended for laboratory research use only and are not presented for human or animal consumption, diagnosis, treatment, prevention, weight management, cosmetic use, or self-administration.